ArticleToxicological research2026
Validation of a B cell acute lymphoblastic leukemia xenograft rat model for integrated efficacy, pharmacokinetics and safety of CD19 CAR-T.
Article in Toxicological research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In preclinical studies of B cell acute lymphoblastic leukemia (B-ALL), mouse models have limitations related to their small body size, which restricts serial sampling required for integrated assessment of efficacy, safety, and pharmacokinetics (PK) assessments. To overcome these limitations, we developed a B-ALL xenograft rat model as an integrated platform for the preclinical evaluation of cell therapies and validated this platform by testing its ability to simultaneously assess efficacy, PK, and safety using a CD19 CAR-T standard. The B-ALL rat model was established using NALM-6 (human B-ALL cell line) cells, followed by intravenous injection of CD19 CAR-T three days later at doses of 1.0 (low) and 2.0 × 10⁸ cells/kg (high). B-ALL xenograft rat model successfully differentiated dose-dependent responses, demonstrating significant tumor regression without adverse effects in high-dose group, whereas low-dose group showed no efficacy. Kinetic analysis revealed peak expansion of CAR-T cells in high-dose group 3 weeks after injection, while low-dose group displayed no significant expansion. Crucially, this study demonstrates the utility of the model as an integrated PK-Efficacy evaluation platform with exploratory safety monitoring. We identified 2.0 × 10⁸ cells/kg as an effective therapeutic dose with a favorable safety profile, showing complete remission without evident toxicity under the tested conditions. This study is the first to validate a B-ALL xenograft rat model capable of simultaneously analyzing efficacy, safety, and biodistribution. By utilizing rats, a species widely accepted in toxicology, this disease-relevant model provides a robust platform to support the preclinical assessment of next-generation cell-based therapies. Supplementary Information: The online version contains supplementary material available at 10.1007/s43188-026-00343-1.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.